Amphotericin B

Biosergen has successfully completed the second patient cohort in its BSG005 proof-of-concept trial, with eight of ten patients showing clinical improvement against life-threatening fungal infections.

F2G's olorofim, the first in a new class of orotomide antifungals, received a complete response letter from the FDA requiring additional data before approval.

Matinas BioPharma's MAT2203, an oral formulation of amphotericin B, demonstrates enhanced survival and reduced fungal burden in preclinical studies.

• F2G has raised $100 million to fund late-stage testing of olorofim, an antifungal drug intended to treat invasive aspergillosis, after initial FDA rejection. • The funding round was co-led by AMR Action Fund and ICG, with participation from eight other investors, signaling strong confidence in olorofim's potential. • Olorofim, an orotomide antifungal, targets a key enzyme in fungi and has received Breakthrough Therapy designation, with ongoing Phase 3 trials comparing it to AmBisome. • The investment will support completion of the Phase 3 trial, resubmission to the FDA, and preparations for the potential U.S. launch of olorofim.

F2G announced positive Phase 2b data for olorofim showing a 44% complete or partial response rate at day 42 in 100 patients with invasive fungal infections who had limited treatment options.